AGP Picks
View all

Cell-free DNA extraction market seen reaching $2.74 billion by 2030

Nov. 10, 2026
Cell-free DNA extraction market seen reaching $2.74 billion by 2030
By AI, Created 14:30 UTC, Nov 10, 2026, AGP -

The cell-free DNA isolation and extraction market is projected to rise from $2.05 billion in 2025 to $2.19 billion in 2026, with growth tied to liquid biopsy, prenatal screening and cancer diagnostics. The Business Research Company says North America led the market in 2025 as demand grows for non-invasive testing and automated workflows.

Why it matters: - Cell-free DNA isolation and extraction is becoming a core tool for non-invasive testing in oncology, prenatal screening and transplant monitoring. - The market's growth reflects rising demand for faster, more precise molecular diagnostics and automation in lab workflows. - The technology supports earlier detection and more tailored treatment decisions, especially as cancer case counts climb worldwide.

What happened: - The Business Research Company published a forecast for the cell-free DNA isolation and extraction global market covering 2026-2035. - The market is expected to increase from $2.05 billion in 2025 to $2.19 billion in 2026. - The report forecasts the market will reach $2.74 billion by 2030. - North America held the largest regional share in 2025. - The report covers Asia-Pacific, Southeast Asia, Western and Eastern Europe, South America, the Middle East and Africa. - The company also promoted a free sample of the report and the full report online: the report sample and the full market report.

The details: - The market's projected 2025-2026 CAGR is 6.6%. - The forecast period from 2026 to 2030 implies a 5.8% CAGR. - Growth has been driven by wider use of liquid biopsy, expanded molecular diagnostics testing, prenatal screening programs, genomic research tools and specialized extraction kits. - Future growth is linked to early cancer detection, precision diagnostics investment, transplant monitoring, automation in molecular laboratories and demand for rapid cfDNA workflows. - Emerging trends include broader non-invasive genetic testing, greater use of magnetic bead-based extraction methods and higher demand for automated cfDNA isolation systems. - The market also is expanding across oncology and prenatal testing applications, with efforts focused on improving DNA yield recovery. - cfDNA isolation and extraction separates DNA circulating outside cells in biological fluids such as blood, plasma, serum and urine. - The process enables genetic analysis without invasive tissue biopsies. - The resulting data can support diagnostic, prognostic and therapeutic assessments.

Between the lines: - Rising cancer incidence is the strongest demand driver because cfDNA testing can help analyze tumors, monitor treatment response and track disease progression. - The American Society of Clinical Oncology reported about 20 million new cancer cases in 2022 and projected 35 million by 2050, with an estimated 9.7 million deaths. - Personalized medicine is another major growth engine because cfDNA can help match treatment to a patient's genetic profile. - The Personalized Medicine Coalition reported that the U.S. Food and Drug Administration approved seven new personalized cancer therapies in 2023. - North America's lead likely reflects stronger healthcare infrastructure, higher research spending and earlier adoption of advanced diagnostics. - The report's added dashboards, scoring tools and hotspot analysis point to a market where buyers and investors are looking for more actionable segmentation data.

What's next: - Demand is likely to keep rising as non-invasive genetic testing expands and more labs automate cfDNA workflows. - Oncology and prenatal testing should remain the biggest application areas to watch. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards and future-trend analysis.

The bottom line: - cfDNA isolation and extraction is moving from a niche laboratory capability to a broader diagnostics platform, with cancer care and personalized medicine driving the next phase of growth.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Coast To Coast Tribune

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Coast To Coast Tribune

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.